Abstract Treatment of BRAF-mutant metastatic melanoma with mitogen-activated protein
kinase (MAPK) pathway targeted therapies (BRAF/MEK inhibitors) and immune checkpoint …

BRAF mutation can be identified in about 45% of the patients with metastatic melanoma. In
these patients, BRAF and MEK inhibitors are able to induce rapid responses and to prolong …

BRAF and MEK inhibitors, alone or in combination, are highly active in the 40% of patients
with BRAF mutant metastatic melanoma. Despite this activity resistance often develops in …

Inhibitors of the mitogen-activated protein kinases (MAPK), BRAF, and MAP–ERK kinase
(MEK) induce tumor regression in the majority of patients with BRAF-mutant metastatic …

Melanoma onset and progression are associated with a high variety of activating mutations
in the MAPK-pathway, most frequently involving BRAF (35–45%) and NRAS (15–25%) …

The efficacy of selective BRAF inhibitors has now been established in the 50% of patients
with metastatic melanoma whose tumors harbor activating mutations. However, for the vast …

Targeted therapy with BRAF inhibitors (BRAFi) and MEK inhibitors (MEKi) provides rapid
disease control with high response rates in patients with BRAF-mutant metastatic …

Background The clinical use of BRAF inhibitors for treatment of metastatic melanoma is
limited by the development of drug resistance. In this study we investigated whether co …

Approximately 50% of melanomas harbor an activating BRAF mutation. Combined BRAF
and MEK inhibitors such as dabrafenib and trametinib, vemurafenib and cobimetinib, and …

Abstract Treatment of BRAF-mutant melanoma with combined dabrafenib and trametinib,
which target RAF and the downstream MAP–ERK kinase (MEK) 1 and MEK2 kinases …